Tarsus Pharmaceuticals trust proposes $802K share sale

Available on EDGAR 11/13/2026 - 05:00 PM EST Accepted by SEC EDGAR 11/13/2026 - 05:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) lists 10,000 common shares for sale by the Bobak Azamian Living Trust, with an aggregate market value of $801,500 and an approximate sale date of November 13, 2026. Bobak Azamian is identified as an officer and the trust’s trustee; the notice gives December 9, 2025 as the Rule 10b5-1 plan adoption or instruction date. Tarsus lists 49,305,552 common shares outstanding.

Key Figures

Shares listed for sale: 10,000 shares Aggregate market value: $801,500 Common shares outstanding: 49,305,552 shares +2 more

5 metrics

Shares listed for sale 10,000 shares Tarsus common shares; approximate sale date November 13, 2026

Aggregate market value $801,500 For the 10,000 common shares listed for sale

Common shares outstanding 49,305,552 shares As listed in the notice

Prior sale on September 2, 2026 10,000 shares; $800,568.71 gross proceeds Sale by the Bobak Azamian Living Trust

Prior sale on September 4, 2026 10,000 shares; $905,587.08 gross proceeds Sale by the Bobak Azamian Living Trust

Key Terms

Rule 10b5-1, Private Placement

2 terms

Rule 10b5-1 regulatory

"if relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Private Placement financial

"Nature of Acquisition Transaction: Private Placement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TARS shares does the Bobak Azamian Living Trust plan to sell?

The notice lists 10,000 common shares for sale, with an aggregate market value of $801,500 and an approximate sale date of November 13, 2026.

What previous TARS sales are listed for the Bobak Azamian Living Trust?

The notice lists 10,000 common shares sold September 2, 2026, for gross proceeds of $800,568.71, and 10,000 shares sold September 4, 2026, for gross proceeds of $905,587.08.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001827672
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tarsus Pharmaceuticals, Inc.
SEC File Number
Address of Issuer	17700 Laguna Canyon Road Floor 4 Irvine CALIFORNIA 92618
Phone	9494181801
Name of Person for Whose Account the Securities are To Be Sold	Bobak Azamian
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 2049 Century Park E Ste 1200 Los Angeles CA 90067	10000	801500	49305552	11/13/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/13/2017	Private Placement	Tarsus Pharmaceuticals Inc			10000	01/13/2017	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Bobak Azamian Living Trust 17700 Laguna Canyon Rd Floor 4 Irvine CA 92618	Common	09/02/2026	10000	800568.71
Bobak Azamian Living Trust 17700 Laguna Canyon Rd Floor 4 Irvine CA 92618	Common	09/04/2026	10000	905587.08

144: Remarks and Signature

Remarks	THIS TRANSACTION TOOK PLACE IN THE BOBAK AZAMIAN LIVING TRUST, BOBAK AZAMIAN TRUSTEE
Date of Notice	11/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Bobak Azamian
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)